Activity and regulation of glycoPEGylated factor.VIIa analogs

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 9, 2008, Pages 1525-1533

  Ghosh, S ^a   Sen, P ^a   Pendurthi, U R ^a   Rao, L Vijaya Mohan ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Factor VIIa; GlycoPEGylated factor ViIIa; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; HEPARIN; MACROGOL; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD CLOTTING; CATALYSIS; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; FEASIBILITY STUDY; HUMAN; HUMAN CELL; MACROMOLECULE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN INTERACTION; PROTEIN VARIANT;

ANTITHROMBINS; CATALYSIS; CELL-FREE SYSTEM; CELLS, CULTURED; FACTOR VIIA; GLYCOSYLATION; HUMANS; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THROMBOPLASTIN;

EID: 49849106445     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03065.x     Document Type: Article

References (26)

1. Hedner U. Recombinant activated factor.VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998; 9 (Suppl.): S147-52.
2. Roberts HR, Monroe DM, White GC. The use of recombinant factor.VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64.
3. Hedner U, Erhardtsen E. Potential role of recombinant factor.VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 1: 112-19.
4. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia.A and B. Acta Orthop Scand Suppl 1965; 77 (Suppl.): 3-132.
5. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years'experience of prophylactic treatment in severe haemophilia.A and B. J Intern Med 1992; 232: 25-32.
6. Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol 1970; 34: 111-24.
7. Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PL, Gringeri A, Ljung RC, Manco-Johnson MJ, Morfini M, Kilcoyne RF, Petrini P, Rodriguez-Merchan EC, Schramm W, Shapiro A, van den Berg HM, Hart C. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
8. Morfini M, Auerswald G, Kobelt RA, Rivolta GF, Rodriguez-Martorell J, Scaraggi FA, Altisent C, Blatny J, Borel-Derlon A, Rossi V. Prophylactic treatment of haemophilia patients with inhibitors: Clinical experience with recombinant factor.VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
9. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of recombinant factor.VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
10. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor.VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
11. Harris JM, Martin NE, Modi M. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-51.
12. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-21.
13. Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv 2006; 13: 399-409.
14. Roseng L, Tolleshaug H, Berg T. Uptake, intracellular transport, and degradation of polyethylene glycol-modified asialofetuin in hepatocytes. J Biol Chem 1992; 267: 22987-93.
15. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 2001; 86: 1716-23.
16. Thim L, Bjoern S, Christensen M, Nicolaisen EM, Lund-Hansen T, Pedersen AH, Hedner U. Amino acid sequence and posttranslational modifications of human factor.VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-93.
17. Bayer RJ, Ostergaard J, Kalo MS, Holm PK, Kinealy K, Sorensen BB, Bjorn SE, Zopf D, Stennicke HR. Develeopment of long-acting factor.VIIa derivatives by glycopegylation. J Thromb Haemost 2007; 5 (Suppl.): P-T-016.
18. Rao LVM, Williams T, Rapaport SI. Studies of the activation of factor.VII bound to tissue factor. Blood 1996; 87: 3738-48.
19. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octylglucoside. Biochemistry 1981; 20: 833-40.
20. Neuenschwander PF, Branam DE, Morrissey JH. Importance of substrate composition, pH and other variables on tissue factor enhancement of factor.VIIa activity. Thromb Haemost 1993; 70: 970-7.
21. Iakhiaev A, Ruf W, Rao LVM. The role of catalytic cleft and exosite residues of factor.VIIa for complex formation with tissue factor pathway inhibitor. Thromb Haemost 2001; 85: 458-63.
22. Ghosh S, Ezban M, Persson E, Pendurthi U, Hedner U, Rao LV. Activity and regulation of factor.VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2006; 5: 336-46.
23. Larsen KS, Ostergaard H, Bjelke JR, Olsen OH, Rasmussen HB, Christensen L, Kragelund BB, Stennicke HR. Engineering the substrate and inhibitor specificities of human coagulation factor.VIIa. Biochem J 2007; 405: 429-38.
24. Stone M, Harvey SB, Kisiel W, Foster D, Nelsestuen GL. Unusual benefits of macromolecular shielding by polyethylene glycol for reactions at the diffusional limit: The case of factor. VIIai and tissue factor. Biochemistry 2002; 41: 15820-5.
25. Sorensen BB, Kjalke M, Zopf D, Bjorn SE, Stennicke HR. Platelet-dependent activity of glycopPEGylated rFVIIa. Blood 2007; 110: 923a.
26. Sorensen BB, Karpf D, Groth AV, Bysted BV, Hermit MB, Tranholm M, Bjorn SE, Kinealy K, Zopf D, Bayer RJ, Kalo MS, Stennicke HR. Effect of glycopegylation on the pharmacokinetic properties of FVIIa. J Thromb Haemost 2007; 5 (Suppl.) P-T-012.